An insight into the presence of impurities in reference standards and their impact on mass spectrometry-based bioanalysis

Papers of special note have been highlighted as: • of interest

References

• 1. Robinson TW, Jacobs A. Metabolites in safety testing. Bioanalysis 1, 1193–1200 (2009).
  Google Scholar
• 2. US FDA. Guidance for Industry: Bioanalytical Method Validation. MD, USA (2018).
  Google Scholar
• 3. EMA. Guidance on Bioanalytical Method Validation. London, UK (2011).
  Google Scholar
• 4. ICH. ICH harmonized guideline: bioanalytical method validation and study sample analysis, M10 (2022). • Summarizes the bioanalytical method validation guidance published by various regulatory agencies and related articles on presence of impurities in standards.
  Google Scholar
• 5. US Pharmacopeia. USP chapters <1086> impurities in drug substances and drug products. In:USP 41. US Pharmacopeial Convention, MD, USA (2018).
  Google Scholar
• 6. ICH. ICH harmonized triplicate guideline: impurities in new drug substances, Q3A (R2) (2006).
  Google Scholar
• 7. US FDA. Guidance for Industry, ANDAs: Impurities in Drug Substances. MD, USA (2009).
  Google Scholar